With six marketed drugs, ADCs are presently recognized as apotent class of targeted anticancer therapies, with the potential to be used totreat a variety of other disease indications. The success of such products canbe attributed to their ability to effectively identify and eliminate diseaseassociated cells / pathogens, with substantially lower risk of treatmentrelated side effects.
To order this 600+page report, which features 190+ figures and 280+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html
The USD 15 billion (by 2030) financial opportunitywithin this market has been analyzed across the following segments:
§ Type of Payload
§ MMAE
§ DM4
§ Camptothecin
§ DM1
§ MMAF
§ Others
§ Type of Linker
§ VC
§ Sulfo-SPDB
§ SMCC
§ VA
§ Hydrazone
§ Others
§ Target Indication
§ Breast cancer
§ Lymphoma
§ Leukemia
§ Urothelial cancer
§ Lung cancer
§ Ovarian cancer
§ Others
§ Target Antigen
§ CD30
§ HER2
§ CD22
§ CD33
§ Others
§ Technology Providers
§ Seattle Genetics
§ ImmunoGen
§ StemCentRx
§ Immunomedics
§ Others
§ Key Geographical Regions
§ North America
§ Europe
§ Asia Pacific
The AntibodyDrug Conjugates Market (5th Edition), 2019-2030.” report features the following companies, whichwe identified to be key players in this domain:
§ Bristol Myers Squibb
§ GlaxoSmithKline
§ Incyte
§ Novartis
§ Trillium Therapeutics
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
1. Market Overview
5. Company and Drug Profiles
6. Key Therapeutic Areas
7. Key Opinion Leaders
8. Target CompetitivenessAnalysis
9. Partnerships andCollaborations
10. Funding and InvestmentAnalysis
11. Patent Analysis
12. Academic Grants
13. Key CommercializationStrategies
14. Promotional Analysis
15. Combination Therapies
16. Novel Conjugation TechnologyPlatforms
17. Assessment of Non-ClinicalData, First in Human Dosing
18. Cost Price Analysis
19. Case Study: ContractManufacturing of ADC
20. Case Study: CompanionDiagnostics for ADC Therapeutic
21. Market Forecast andOpportunity Analysis
22. Swot Analysis
23. Conclusion
24. Executive Insights
25. Appendix 1: Tabulated Data
To purchase a copy,please visit https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
